The ITFG2 Knouckout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population designed for loss-of-function studies of ITFG2 in the A-549 human lung adenocarcinoma cell line. This heterogeneous pool of edited cells enables robust gene-function analyses without clonal-selection artifacts, making it ideal for cancer biology and signal transduction research.
A-549 is a widely used model for non-small cell lung carcinoma, established from a 58-year-old Caucasian male. Its epithelial nature and retention of key oncogenic pathways, including integrin signaling, make it an appropriate host for investigating adhesion, migration, and tumor progression.
ITFG2 encodes an integrin-associated protein known to function downstream of T-cell receptor stimulation and CD28 co-stimulation in lymphoid cells, regulated by NFAT and NF-??B. It interacts with integrin alpha chains and focal adhesion kinase (FAK), positioning it at a nexus between adhesive and growth-factor signaling. In A-549, ITFG2 disruption likely impairs integrin activation and dampens PI3K/Akt and MAPK cascades, altering NF-??B and AP-1 transcriptional responses. Canonical mediators include the TCR?CZAP-70?CLAT?CSLP-76 axis, ITK, PLC??1, PKC??, CARMA1?CBCL10?CMALT1, IKK, JNK, and AP-1, many of which also participate in adhesion and survival pathways in epithelial cells.
This A-549 ITFG2 knockout population offers a physiologically relevant system for dissecting mechanisms of lung adenocarcinoma cell adhesion, migration, and invasion. Loss of ITFG2 may uncover vulnerabilities in integrin-dependent survival signals that drive metastatic dissemination, facilitating the identification of novel therapeutic targets. The polyclonal format preserves genetic heterogeneity, enabling robust, statistically powered screens and dose-response studies.
Applications include western blotting, RT-qPCR, and Sanger sequencing for knockout validation; immunofluorescence for focal adhesion proteins; adhesion, migration, and invasion assays; and phospho-signaling analysis of pFAK, pAkt, and pERK. Flow cytometry can quantify surface integrin expression, while apoptosis and viability assays evaluate cell fate. Transcriptomic profiling via RNA-seq can reveal global pathway rewiring. These cells are well suited for integrin signaling research, drug target screening for anti-metastatic compounds, and tumor microenvironment investigations. For further details, please contact Ascent Research.
